- ￥425
- Sigma-Aldrich
- 进口
- 27487-250G-F
- 2025年09月12日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
常温
- 保质期：
根据瓶身LOT号查询
- 英文名：
Citric acid
- 库存：
有现货
- 供应商：
浙江羽翔生物科技有限公司
- CAS号：
77-92-9
- 规格：
250G
属性
等级
biotech. grade
质量水平
200
产品线
BioUltra
方案
≥99.5% (T)
表单
powder or crystals
expl. lim.
8 %, 65 °F
技术
cell culture | hybridoma: suitable
杂质
insoluble matter, passes filter test
灼烧残渣
≤0.05% (as SO4)
缺失
≤0.5% loss on drying, 110 °C
pH值（酸碱度）
1.0-2.0 (25 °C, 1 M in H2O)
pKa
(1) 3.13, (2) 4.76, (3) 6.4
mp
153-159 °C (lit.)
溶解性
H2O: 1 M at 20 °C, clear, colorless
痕量阴离子
chloride (Cl-): ≤5 mg/kg
oxalate (C2O42-): ≤0.05%
phosphate (PO43-): ≤5 mg/kg
sulfate (SO42-): ≤20 mg/kg
tartrate (C4H4O62-): ≤0.20%
痕量阳离子
Al: ≤5 mg/kg
As: ≤0.1 mg/kg
Ba: ≤5 mg/kg
Bi: ≤5 mg/kg
Ca: ≤10 mg/kg
Cd: ≤5 mg/kg
Co: ≤5 mg/kg
Cr: ≤5 mg/kg
Cu: ≤5 mg/kg
Fe: ≤5 mg/kg
K: ≤50 mg/kg
Li: ≤5 mg/kg
Mg: ≤5 mg/kg
Mn: ≤5 mg/kg
Mo: ≤5 mg/kg
Na: ≤50 mg/kg
Ni: ≤5 mg/kg
Pb: ≤5 mg/kg
Sr: ≤5 mg/kg
Zn: ≤5 mg/kg
SMILES字符串
OC(=O)CC(O)(CC(O)=O)C(O)=O
λmax
260 nm (Amax: ≤0.20)
280 nm (Amax: ≤0.10)
λ
1 M in H2O
紫外吸收
λ: 260 nm Amax: 0.20
λ: 280 nm Amax: 0.10
InChI
1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
InChI key
KRKNYBCHXYNGOX-UHFFFAOYSA-N
基因信息
human ... SRC(6714)
一般描述
应用
- 改善土壤微生物组：柠檬酸已经被用于改变含盐泥滩的土壤细菌菌群，研究显示了其在可持续生态管理环境生物技术中的用途
- 食品工业中的可生物降解包装：在食品化学领域，柠檬酸和聚乙烯醇被用于开发抗微生物包装，体现了其在食品安全和保藏中的潜力。
- 工程应用中的纳米材料合成：柠檬酸是用于超级电容器的杂化纳米材料绿色合成的关键成分，该研究强调了其在促进材料科学和工程的作用。
- 环境科学和污染物控制：该研究采用柠檬酸考察了环境系统中药物和纳米颗粒的共运输，有助于理解污染物动力学和迁移策略。
- 食品科学和技术：研究人员在素食软糖配方中使用了柠檬酸，该研究显示了其在食品开发中的多功能性及其对质构特性的影响。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Structure-guided residence time optimization of a dabigatran reversal agent.
Novel oral anticoagulants are effective and safe alternatives to vitamin-K antagonists for anticoagulation therapy. However, anticoagulation therapy in general is associated with an elevated risk of bleeding. Idarucizumab is a reversal agent for the direct thrombin inhibitor, dabigatran etexilate (Pradaxa®) and is currently in Phase 3 studies. Here, we report data on the antibody fragment aDabi-Fab2, a putative backup molecule for idarucizumab. Although aDabi-Fab2 completely reversed effects of dabigatran in a rat model in vivo, we observed significantly reduced duration of action compared to idarucizumab. Rational protein engineering, based on the X-ray structure of aDabi-Fab2, led to the identification of mutant Y103W. The mutant had optimized shape complementarity to dabigatran while maintaining an energetically favored hydrogen bond. It displayed increased affinity for dabigatran, mainly driven by a slower off-rate. Interestingly, the increased residence time translated into longer duration of action in vivo. It was thus possible to further enhance the efficacy of aDabi-Fab2 based on rational design, giving it the potential to serve as a back-up candidate for idarucizumab.
技术资料暂无技术资料 索取技术资料
